Brent Saunders

Senior Advisor

Brent currently serves as the CEO and Chairman of Bausch + Lomb. Previously, Brent was Chairman, President and CEO of Allergan plc. until the company’s $63 billion acquisition by AbbVie Inc in 2020. Prior to Allergan, Brent was President and CEO and a director of Forest Laboratories Inc., until that company’s $25 billion merger with Actavis plc. in 2014, when he was named CEO of the combined business. Brent then successfully led Actavis’ $66 billion acquisition of Allergan. Brent currently serves as Chairman of the Board of The Beauty Health Company (Nasdaq: SKIN) and as a director of ARS Pharmaceuticals, Inc. (Nasdaq: SPRY). Brent is Chairman of the Board of Roam, a director of Cambrian BioPharma and Fifth Down portfolio company Arena AI, and a Nextech board advisor.

Senior Advisors and Operating Partners are non-control advisors. These individuals are not employees of Fifth Down Cap LLC (“FDC”) or any of the funds or SPVs managed by FDC or its affiliate, Fifth Down Capital Partners, LLC (together with FDC, “Fifth Down”). Certain of the Senior Advisors and Operating Partners are engaged by FDC to provide consulting services. Consultants may be compensated with fees for such services. Additionally, Senior Advisors and Operating Partners may receive incentive unit grants in FDC and grants of carried interest in funds or vehicles managed by Fifth Down. Further, Senior Advisors and Operating Partners may be investors, directly or indirectly, in FDC, Fifth Down funds or vehicles, and/or existing and prospective portfolio companies and may receive fee breaks in connection with such investments.